
The first-in-human trial of a CRISPR-Cas9 gene therapy delivered by adeno-associated virus 9 to target the latent HIV proviral genome showed a promising safety profile and potential efficacy in reducing the HIV reservoir in at least one participant.


coremsg

The CRISPR Cas system delivered by adeno-associated virus 9 gene therapy to treat HIV was able to target only the intended DNA and cleared the blood in 6 months.

First-in-Human Trial of CRISPR Gene Therapy for HIV

first-in-human-trial-of-crispr-based-gene-therapy-for-hiv-demonstrates-safety-and-promising-results


First-in-Human Trial of CRISPR-Based Gene Therapy for HIV Demonstrates Safety and Promising Results
